Table 1.

Association of common genomic alteration with overall survival and time on treatment with first-line ARSI

Gene/pathway alterationUnivariate P value for survival from first-line ARSI (CPE, n = 128 or as indicated)Univariate P value for time on treatment with first-line ARSI (CPE, n = 108 or as indicated)
RB10.002 (CPE 0.768)<0.001 (CPE 0.818)
TP530.072 (CPE 0.605)0.046 (CPE 0.609)
WNT pathway0.1150.153
ETS fusion0.1590.206
APC0.2550.167
CTNNB10.2740.448
ATM0.3310.850
BRCA20.3270.418
BRCA2/BRCA1/ATM0.4950.611
AKT10.5580.053
RNF430.6140.844
AR0.6580.005 (CPE 0.651)
PTEN0.6760.412
PI3K pathway0.6990.138
PIK3CA0.7160.165
PIK3R10.7520.892
PIK3CB0.7990.277
BRCA10.8090.998
NEPC score0.218 (n = 99)0.930 (n = 80)
AR signaling score0.847 (n = 99)0.847 (n = 80)
RB1 loss score<0.001 (n = 99)0.014 (n = 80)
CCP score0.002 (n = 99)0.045 (n = 80)
AR-V7 SRPM0.524 (n = 75)0.329 (n = 56)
AR-V7/ARpromoter1-20.475 (n = 75)0.378 (n = 56)
AR-V3 SRPM0.444 (n = 75)0.077 (n = 56)
  • Univariate log-rank analysis for association of common genomic alterations with survival from the start of a first-line ARSI for mCRPC (n = 128), and with time on treatment with a first-line ARSI for mCRPC (n = 108 patients who received a first-line ARSI as monotherapy). Where indicated, analysis was limited to a subset of patients who had RNA-sequencing data either from polyA libraries or both polyA and capture libraries. P < 0.05 are highlighted in bold.